SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as the community anticipates potential catalysts and discusses key resistance levels to watch. Optimism is fueled by speculation around a possible ETF and increased adoption, with many hoping to see it reach higher price targets. Some traders suggest a cup and handle formation may be developing.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the community anticipates potential ETF approvals and discusses technical indicators suggesting a possible breakout. Community members are debating potential price movements, with some expressing excitement about potential gains, while others remain cautious. Discussions include the potential impact of regulation and real-world asset tokenization on XRP's future.

Ainalyzr is a versatile and engaging platform designed to provide crypto traders with advanced tools and a fun, interactive environment. Powered by the Ainalyzr token, it offers real-time analysis of Solana-based tokens, gamified trading tools, and a space for users to explore market trends and make data-driven decisions. Ainalyzr merges functionality and entertainment, appealing to both seasoned and novice traders.

AInalyzr

AInalyzr ($AINAL.X) is gaining attention, with community members highlighting its potential for a breakout and comparing it to early investments in established cryptocurrencies. Talk centers on the token's chart patterns, suggesting a possible surge, and the opportunity for early investors to benefit. The crypto is being touted as the next big play, urging others to stack now before it takes off.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending with community members actively discussing potential pumps and comparing it to other meme coins like Doge and Bonk. Some traders are debating the merits of holding SHIB, while others express excitement about its potential. There is also chatter about the broader meme coin season and potential catalysts for SHIB.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as community members highlight activity around $AINAL.X, with many claiming it is poised for a breakout and urging others to get in early. Bullish sentiment also surrounds potential ETF listings and institutional investment, with some anticipating a significant price increase for SOL.X.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin is trending as the crypto community anticipates potential market movements influenced by the upcoming Fed announcement, with some predicting significant volatility. Community members are closely watching for breakout patterns, with much of the conversation centered around a potential surge related to $AINAL.X. The broader discussion includes speculation on rate cuts and their impact on Bitcoin's price.

$JINGLE  is a meme community on Solana, The project was fair-launched on Pump.fun, This is a purely community-driven project.  $JINGLE a community powered token celebrating global holidays!  With a dedicated team and a vibrant community, $JINGLE Token aims to bring joy and prosperity to holders while embodying the spirit of the internet's favorite amphibian. Jump on board and let's make waves in the crypto pond together!

Jingle

$JINGLE.X is gaining traction as the community rallies around potential gains, emphasizing 'early entry' for future profits. Discussions highlight its potential, with community members expressing conviction in its long-term prospects, drawing comparisons to early investments in established cryptocurrencies. The community buzz suggests a focus on accumulating $AINAL.X, encouraging patience and strong hands.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery is trending amid speculation of a potential acquisition by Paramount Skydance, driving significant market activity. Community discussions revolve around the strategic implications of the merger, potential bidding wars with other media giants, and speculation around the final buyout price. Investors are weighing potential synergies and regulatory hurdles in the ever-consolidating media landscape.

Trump For President

$TRUMP.X is trending amidst discussions about its potential and association with Donald Trump, with some traders weighing in on technical analysis and potential price movements. Conversations also involve heated political debates and comparisons to other meme coins. Some users reference an ETF filing, while others discuss the coin's performance relative to Bitcoin and other cryptocurrencies.

Volatility Shares Trust - 2x Ether ETF

Volatility Shares 2x Ether ETF

ETHU is trending as traders discuss its potential for leveraged gains amidst fluctuating Ether prices, with some cautioning about the ETF's volatility and compounding decay. The community is actively weighing short-term trading opportunities against the risks of longer-term holds, as ETH attempts to break key resistance levels. Overall sentiment suggests ETHU remains a popular instrument for those seeking amplified exposure to Ether's price movements.

statis crypto Watchlist

Ethereum

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MELBOURNE, Australia, Sept. 12, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company,” NASDAQ: GELS), a clinical and science-based developer of gel-based oral delivery solutions, welcomes the recently&nbsp;announced product launches of <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=m_DdCQTpOIEkyMW6a_LTNu80nA-fvUjxL3WRLmnGS69pjlEjzE7uri5nWw8o-jN5ufZ7dm_TD-F_EgPyk3wUaQdHmXCqk3fv6wOqrJUixIc=">Healthy Extracts, Inc.</a>(“Healthy Extracts,” OTCQB: HYEX), whose products apply Gelteq’s proprietary gel technology, <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=jVTfFSVxnjolcQWdJUHguUDpIFQsKOiqOBXBpcPqudxVaqM7qCSY6qp7CcK5vPQJFCo7hIArwK5VrglasVoSV6fkl1MhXuC0Z8-hE_a4204rIsukKFHSs6N8s2fDFE3nNeNsvZBeBaVYTKiPqDW3LCAe7Pbvi1Ykp2jwWuGNhVBrcGVtaGDqvv_XCRaSX9V2pmGKXGiBfHNkQZ7JeBNpdl8KBByCsg5_bPZoMX49Lldu2oACh7Wdw4rKa5E1y6JJfaWZzk6107bQ3c5yeCotSV3KY6uN9ysKWvWsic3iFkfv13xMn1h_G_ovXuIFktP5">into the U.S. nutraceutical market</a>.The Healthy Extracts products are the first to reach Gelteq’s U.S. warehousing facility using Gelteq’s delivery platform, an important milestone that marks Gelteq’s transition from R&amp;D to active commercialization in the U.S. This development highlights both the growth potential of Gelteq’s technology in large-scale wellness markets in the U.S. and its ability to meet consumer demand for innovative, convenient, and clinically-informed formats.“We are pleased to see Gelteq’s technology expand into the U.S. market through our collaboration with Healthy Extracts,” said Nathan Givoni, CEO of Gelteq. “Healthy Extract’s launch demonstrates how our gels can be adapted to create differentiated, consumer-friendly solutions, while paving the way for additional products and partnerships across the U.S. market.”The collaboration with Healthy Extracts, first announced earlier this year, began with warehousing and fulfilment arrangements which laid the foundation for Gelteq's entry into the U.S. market. With this launch, the partnership with Healthy Extract has advanced into active sales and distribution, underscoring the growing momentum behind Gelteq’s gel delivery system and the potential for additional partnership opportunities in the U.S.About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=CzDiesrgFr3dtr9zZyTAj8WQwqMRYCl9wExZjU5Avfu8KSGuGlzGWsggV7F94VXP7gCRfpAAoHjXJ2X5fMFejCkzv8bsd_YZymXULDOahWLGd0vI2gPkcqhcg17_0Yfr">www.gelteq.com</a>.Gelteq Contact: Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission (“SEC”), including its Annual Report on Form 20-F filed on November 15, 2024 and its Registration Statement on Form F-1 initially filed with the SEC on July 1, 2025. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Technology Powers U.S. Product Launches of its Nutraceutical Products for Partner

Gelteq has entered the U.S. market and transitioned from research and development to commercialization with the launch of gel-based products by its partner, Healthy Extracts.

Others

MELBOURNE, Australia, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today announced plans to commence a preclinical bioequivalence study in September 2025 to evaluate its novel gel-based formulation of a widely used antihistamine for allergy treatment. The study will be conducted by Adgyl Lifesciences (a partner of Eurofins Advinus), a leader in preclinical contract research services.If preclinical results are successful, Gelteq anticipates advancing to human clinical trials targeting U.S. Food and Drug Administration (FDA) approval via the 505(b)(2) regulatory pathway.“Our gel-based delivery platform is expected to transform traditional pharmaceutical products currently available on the market, especially where patient compliance and dosage control are critical,” said Nathan Givoni, CEO of Gelteq. “By applying our technology to a well-established antihistamine, we see a significant opportunity to capture value in the allergy market, where patient-friendly formats and flexible dosing remain unmet needs.”Allergic conditions affect over 50 million people annually in the United States alone (1). The global antihistamine market was valued at approximately USD $9 billion in 2023 growing at a 6% CAGR, projected to reach over USD $12 billion by 2028 (2). Demand spans paediatric, adult, and increasingly, animal health (3), reflecting the diverse applications for antihistamine therapies.Gelteq’s proprietary gel formulations aim to address key limitations of traditional tablets and syrups, including palatability challenges for children, swallowing difficulties for elderly patients, and precise dosing needs in veterinary medicine (3).“Our innovative gel technology offers potential advantages in taste masking, ease of administration, and flexible dosing,” added Mr. Givoni. “These attributes are particularly relevant in paediatrics and veterinary care where delivering effective allergy treatments can be challenging.”About Gelteq Ltd.Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company dedicated to developing and commercialising gel-based oral delivery solutions for prescription drugs, nutraceuticals, pet care, sports nutrition, and other applications. Gelteq’s proprietary formulation technology aims to address challenges associated with conventional drug delivery, including taste masking, swallowing difficulties, and precision dosing. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=O19-A9YeYzwuzvF6uGAfqtDG5RRZjNh8mE7N1rM43qWuYEEherjJSFHi9Ncl812p3GbOQCQNBsWSS797RiLzww==">www.gelteq.com</a>.Gelteq Contact:Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 mkreps@darrowir.comForward-Looking StatementsCertain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained herein are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied in such statements. For a discussion of these risks and uncertainties, refer to Gelteq’s filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 20-F filed on November 15, 2024. Gelteq undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.References<ol style="list-style-type:decimal;"><li>American College of Allergy, Asthma &amp; Immunology. (2023). Allergy facts. American College of Allergy, Asthma &amp; Immunology. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2GA_gxthxCKK2am7PO7NqJTQcy2YC8ka5Kcte6IYk-_rkMMxzQMPvg2HqpjhYc9h72dvj8f127hx_V37sDA6KM=">https://acaai.org/allergies/</a></li><li>Grand View Research. (2024, March). Antihistamine market size, share &amp; trends analysis report. Grand View Research. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH8PA2iF4YPFOJnnXWrzLVPWX86_Wv7NSRcESK7JjTDN70jZpuPqpdsx_TBhsE_ulMsIgBJxpUBj13R4ETgeMYf2vk4jcPQISkwfsg1zYJE63DSmPuNhJhhBdTdUIzZKfJ9KWwDWruOryJwg7nm8RSHcuoR3YA-Wn6p7-YvPDoF3fCQ0atmiqwvReNLCbM7tPS-i_fie6yjzGM21gSt4TLW8X8McYSh-w8FfqP1mvol0z">https://www.grandviewresearch.com/industry-analysis/antihistamine-market</a></li><li>MarketsandMarkets. (2023, November). Veterinary dermatology drugs market by product, animal type, route of administration, end user – Global forecast to 2028. MarketsandMarkets. <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=BNccLheL2BHDT5LVrxyDH2Y1c895h1WrE2q8doDlYL1Ih6-5ysKO0PaJX-tphZJJStCjpjTLUUpMpUV9mhXVNK5FNLLa-zQHGWQ_B54syEdWd1IfeFXhWlqU7sjNYhquPgonhJoiVzv-ITdIV85I8IM23Z11Bfhxpq1a1_GLzd4eL402y-zBojIsxjwBqtdEDB_GkSWA1jEq6FQ_hAJ20teMk3pmiCXapAHCSC97v8t-RGifPW7uovJqJo2C_PfBuJyCntgc2WPWifTl4gP1FwrDiGwagc9NPUwLVWidNu47-s8qC0JOu9g0EzXQHXrvMq8x9Bg8Kt0gb5gX1HJARQ==">https://www.marketsandmarkets.com/Market-Reports/veterinary-dermatology-drugs-market-177021512.html</a></li></ol>Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market

Study to Support Potential FDA Approval via 505(b)(2) Pathway

Jul. 17, 2025 8:30 AM ET<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#source=section%3Amain_content%7Csection_asset%3Ameta%7Cfirst_level_url%3Aarticle%7Csymbol%3AGELS">Gelteq Limited (GELS)</a>GlobeNewswireNEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (<a target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/symbol/GELS#hasComeFromMpArticle=false#source=section%3Amain_content%7Cbutton%3Abody_link">GELS</a>) (“Gelteq” or the “Company”), a clinical and science-based company focused on developing and commercializing white label ingestible gel-based solutions for prescription drugs, nutraceuticals, pet care, sports and other products, today announced it has entered into a memorandum of understanding with IDT Australia (ASX: IDT) for a dedicated, locally based manufacturing facility to support the development and scale up of its gel-based products across diverse global pharmaceutical, nutraceutical and animal health markets.IDT is internationally recognized for its expertise in pharmaceutical projects and contract manufacturing services developed across more than 50 years of operation and over 60 market-based drugs. The company specializes in pharmaceutical product development and cGMP manufacture including high containment, high potency manufacture of Active Pharmaceutical Ingredients (API), oral and sterile dose FDA and TGA approved laboratory testing, and clinical packaging. IDT is also at the forefront of developing and manufacturing advanced therapies including mRNA and Antibody Drug Conjugates (ADCs).“Partnering with IDT to establish a locally-based, purpose-built manufacturing facility strategically positions Gelteq to accelerate and scale our products for the global nutraceutical, pharmaceutical and animal health markets,” said Nathan Givoni, CEO of Gelteq. “IDT not only brings proven development, manufacturing and regulatory expertise to support our goals, but also a unique knowledge base to speed up the development of new products targeting these markets.”Paul McDonald, CEO of IDT Australia, commented: “We are excited to combine IDT’s proven development and manufacturing capabilities with Gelteq’s innovative delivery system for wellness and therapeutic products. Gelteq’s proprietary gel technologies offer distinct benefits in both delivery and combination therapy opportunities needed to improve care and dosing compliance across many end markets.”Highlights of the Agreement:<ul><li>Facilities and Equipment required for the manufacture of Gelteq products, in a dedicated building and purpose-built facility, trained staff and operational support.</li><li>Compliance and Certification necessary for products in the therapeutic, veterinary and nutraceutical markets across various product presentations, including regulatory requirements, permits, and licenses from the APVMA, FDA, and TGA.</li><li>Rapid Scale Up Capability to integrate additional manufacturing space and equipment to support growth. &nbsp;</li></ul>About Gelteq Ltd. Headquartered in Melbourne, Australia, Gelteq (NASDAQ: GELS) is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports and other products. Gelteq advances and commercializes its delivery solutions within five core verticals: pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications, and sports nutrition.The Company’s unique formulation directly addresses the issues associated with traditional drug delivery methods such as difficulty swallowing, taste of unpalatable ingredients, and dosage control. For more information, visit <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=00K18qA_R_h14eUsBeqQWCgMgMmxuWb3BtGKz6ILL5yQ1_R8YgVe3aEx_L8wLAZZPAeltknTuVaIh-pb4Kiy8g==">www.gelteq.com</a> and our SportsGel brand website <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=-p3-I0mUlJnWPMf-dUcDiLZEc5RjeyAm-S2zUBjuzZqsz6gVrldwGFhUq191BEReZ8bR_Byc31VTexJpTREpLHRAjbEauYCyxSObvUI2IKY=">www.sportsgel.com</a>.Gelteq Contact:&nbsp; Investor Relations Matt Kreps, Darrow Associates IR +1-214-597-8200 <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/Tracker?data=lXdnLIhrjHSBfmEF8ctV8ZAmFeM-Ds7RVQBML108A473uXIgHycUxnGOSxVLrfBanFWPU-bmwMn1gK9Fn6lO2U8ADzIpjoyqaUQJQBtbSJM=">mkreps@darrowir.com</a>Forward-Looking Statements Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Gelteq’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the timing and fulfilment of current and future orders relating to Gelteq’s products, the success of new programs, the ability to implement a new strategic plan and the success of a new strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Gelteq in general, see the risk factors in its Annual Report on 20-F filed on November 15, 2024. All such forward-looking statements speak only as of the date they are made, and Gelteq undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise.Source: Gelteq Limited 2025 GlobeNewswire, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Gelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing Facilities

https://seekingalpha.com/pr/20169476-gelteq-announces-agreement-with-idt-australia-to-secure-dedicated-new-product-development-and

Shares of Gelteq (GELS) soared 71% on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.gelteq.com/news-events/press-releases/detail/103/gelteq-expands-u-s-operations-with-healthy-extracts-inc">announced</a> an exclusive logistics and distribution agreement with Healthy Extracts Inc. in a bid to expand operations in North America.The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. Healthy Extracts is a publicly traded company focused on plant-based health supplements.Gelteq expects to rapidly scale the distribution of its white-label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, sports, and other products across the United States and Canada, while significantly reducing costs and boosting revenue potential.Under the new agreement, Healthy Extracts will manage all product receiving, secure warehousing, inventory, and order fulfillment from its Henderson, Nevada, facility. The collaboration is expected to reduce fulfillment costs and unlock high-margin revenue opportunities for both Gelteq and Healthy Extracts.“We believe this is a scalable, profitable model for both companies and our shareholders,” said Duke Pitts, President of Healthy Extracts.The initial products to be received under this new agreement are on track for market distribution by the third quarter (Q3) of 2025.On Stocktwits, retail sentiment around Gelteq jumped from ‘extremely bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_10_at_1_19_18_PM_png_58ec493774.webp" alt="GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits" width="628" height="64"><figcaption>GELS's Sentiment Meter and Message Volume as of 1:15 p.m. ET on June 10, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/GELS">GELS stock</a> is up by about 22% this year and down by about 1% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/us-fda-places-clinical-hold-on-gilead-trials-of-two-investigational-hiv-treatments/chl7qNLRbzY">US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes

The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner.

Equity

Gelteq Ltd. operates as a biotechnology company. It focuses on the development and commercialization of white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care, and other products. The firm also offers edible gels. The company was founded by Nathan J. Givoni and Simon H. Szewach on October 15, 2018 and is headquartered in Melbourne, Australia.

GELS
Gelteq Ltd.

Feed

News

Sentiment

Fundamentals

Info

Latest GELS News

GELS Gelteq Ltd.